Tr1x: Funding, Investors & Team (Oct 2026)
Tr1X is a biotechnology company that specializes in the development of allogeneic engineered regulatory T (Treg) and chimeric antigen receptor Treg (CAR-Treg) cell therapies aimed at treating autoimmune and inflammatory diseases. Tr1X's lead investigational therapy, TRX103, is an allogeneic engineered T cell product derived from CD4+ cells sourced from healthy donors, designed to mimic the function of Type 1 regulatory T (Tr1) cells. The U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for TRX103, allowing the initiation of clinical trials for treatment-refractory Crohn’s Disease. Additionally, Tr1X has received an $8 million grant from the California Institute for Regenerative Medicine (CIRM) to support the TRX103 Phase 1/2a clinical trial for Graft-Versus-Host Disease.
Tr1x has raised $58.0M across 2 funding rounds on record, the most recent an undisclosed round of $50.0M announced in Oct 2025.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Tr1x Company Profile and Key Stats
Latest funding round on record: Oct 2025.
Tr1x Funding Rounds
Tr1x raised $8.0M in an undisclosed round announced in Apr 2025.
6 months later, an undisclosed round of $50.0M was announced in Oct 2025.
Tr1x Founders and Leadership Team
No contact details are on record for this team yet.
Tr1x Funding Compared to Other Biotechnology Startups
Tr1x's latest round of $50.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Tr1x in Biotechnology and San Diego
Companies Similar to Tr1x
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Tr1x Funding FAQs
What does Tr1x do?
Tr1X is a biotechnology company that specializes in the development of allogeneic engineered regulatory T (Treg) and chimeric antigen receptor Treg (CAR-Treg) cell therapies aimed at treating autoimmune and inflammatory diseases. Tr1X's lead investigational therapy, TRX103, is an allogeneic engineered T cell product derived from CD4+ cells sourced from healthy donors, designed to mimic the function of Type 1 regulatory T (Tr1) cells. The U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for TRX103, allowing the initiation of clinical trials for treatment-refractory Crohn’s Disease. Additionally, Tr1X has received an $8 million grant from the California Institute for Regenerative Medicine (CIRM) to support the TRX103 Phase 1/2a clinical trial for Graft-Versus-Host Disease.
How much funding has Tr1x raised?
Tr1x has raised $58.0M across 2 rounds on record. The most recent is an undisclosed round of $50.0M announced in Oct 2025.
When did Tr1x last raise funding?
Tr1x's most recent funding round on record is an undisclosed round of $50.0M, announced in Oct 2025.
Who founded Tr1x?
FundedIQ lists David De Vries (Founder), Maria Grazia Roncarolo (Founder) at Tr1x.
Where is Tr1x headquartered?
Tr1x is based in San Diego, California, United States.
How many employees does Tr1x have?
Tr1x is in the 11-50 employee band.
How does Tr1x's funding compare to other Biotechnology startups?
Tr1x's latest round of $50.0M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Tr1x Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Tr1x is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.